Information for

Clinical caregivers are central to advances for patients with kidney diseases. As key stakeholders, clinicians can increase awareness and participation in the KPMP. Readily available study information and videos of patient experiences are provided to bring the KPMP to a broad clinical community.

Study Criteria

KPMP enrolls participants with CKD or AKI. CKD participants may have diabetic kidney disease or hypertensive kidney disease. Inclusion criteria for each study cohort and the general exclusion critieria is listed below.


Diabetic Kidney Disease (Type 1 or 2)

  • eGFR 30-59mL/min/1.73m2 OR
  • eGFR ≥ 60 with UPCR >150mg/g or UACR >30 mg/g

Hypertensive Kidney Disease

  • eGFR30-59/min/1.73m2 with UPCR or UACR
  • eGFR ≥ 60 with UACR 30-2000mg/g or UPCR 150-2000 mg/g

Acute Kidney Injury

  • Baseline eGFR >45mL/min/1.73m2
  • Elevated serum creatinine ≥1.5x baseline, AND one of the following:
  • Further serum creatinine increase of 0.3 mg/dL
  • Positive kidney injury urine biomarkers (NGAL, Kim1, TIMP2 x IGFBP7)
  • Urine microscopy suggestive of ATN

Healthy Reference Groups

  • Undergoing percutaneous nephrolithotomy for treatment of symptomatic renal stones without evidence of pyelonephritis
  • Participating in a living donor kidney transplantation as the donor


  • Age (<18 years)
  • Glomerular disease, Kidney transplant, Pregnancy
  • Increased biopsy complication risk (Chronic anticoagulation, Platelets <100, INR>1.4, Hb <9, aspirin intake within 7 days of biopsy, Hypotension or BP that cannot be controlled to >160/100mmHg at time of biopsy).

Study procedures

KPMP participants are asked to do the following:

  • Have a biopsy of their kidney for research purposes.
  • Give blood, urine and stool.
  • Provide our study team with information about them.
  • Talk to our study team 2-3 times a year for up to 10 years.

Clinician Resources

publications icon

Clinician Primer

Information about the study for clinicians

publications icon


Informational brochure for patients

protocols icon


Frequently asked questions for patients

antibodies icon


KPMP Overview Powerpoint presentation

antibodies icon

AKI Fact sheet

Talking points brochure for clinicians with AKI patients

antibodies icon

CKD fact sheet

Talking points brochure for clinicians with CKD patients

Site Contacts

If you have a patient who would be a good candidate for KPMP, you can reach out to your nearest study center for more information.

Chronic Kidney Disease (CKD)


Brigham & Women’s Medical Center


Ingrid Onul
(617) 638-7332

Site investigator:
Sushrut Waikar, MD, MPH

Joslin Diabetes Center/Beth Israel Deaconess Medical Center


Neil Roy
(617) 309-4130

Site investigator:
Sylvia Rosas, MD


Cleveland Clinic


Leslie Cooperman, RN
(216) 444-7954

Site investigator:
John Sedor, MD


UT Southwestern


Nancy Wang
(214) 615-8291

Site investigator:
Miguel Vasquez, MD

Acute Kidney Injury (AKI)


Yale University

(New Haven)

Angela Victoria-Castro
(203) 737-1787

Site investigator:
F. Perry Wilson, MD


Johns Hopkins University


Pam Corona Villalobos, MD
(410) 955-3852

Site investigator:
Chirag Parikh, MD, PhD

New York

Columbia University

(New York)

Karla Mehl, MD
(212) 851-5216

Site investigator:
Andrew Bomback, MD, MPH


University of Pittsburgh


KPMP team
(412) 958-0957

Site investigator:
Paul Palevsky, MD

Get involved

We value the input of clinicians as we work to grow our study. The KPMP Community Engagement Committee is made up of KPMP site members,patient partners, ethicists and community clinicians. The group meets monthly to receive updates on the study and discuss issues of interest.

If you are interested in participating in the KPMP Community Engagement Committee, please reach out to Ashveena Dighe (

Please Upgrade Your Browser.

Unfortunately, Internet Explorer is an outdated browser and we do not currently support it. To have the best browsing experience, please upgrade to Microsoft Edge or Google Chrome.